$Humanigen, Inc.(HGEN)$ NIH Ad_老虎社区_美港股上老虎

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19

ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR study

Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L

Study modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)

Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":802987842,"tweetId":"802987842","gmtCreate":1627707366786,"gmtModify":1631886325627,"author":{"id":3574830102097482,"idStr":"3574830102097482","authorId":3574830102097482,"authorIdStr":"3574830102097482","name":"Klim8898","avatar":"https://static.tigerbbs.com/d68dfa512fc1b366a9d0046a0cca6701","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><a href=\"https://laohu8.com/S/HGEN\">$Humanigen, Inc.(HGEN)$</a>NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR studyPrimary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/LStudy modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/HGEN\">$Humanigen, Inc.(HGEN)$</a>NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR studyPrimary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/LStudy modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B</body></html>","text":"$Humanigen, Inc.(HGEN)$ NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19 ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR study Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L Study modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA) Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/802987842","repostId":0,"isVote":1,"tweetType":1,"viewCount":996,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HGEN"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":535,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/802987842"}